14.3: Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For Parkinson's Disease Psychosis, atypical antipsychotics are the preferred treatment.

The primary goals of this acute antipsychotic treatment are to reduce agitated behavior, improve thought organization, and decrease social withdrawal. However, treatment adherence is often challenging due to adverse drug events, cognitive dysfunction, substance use, and patients' limited insight into their own illness. These difficulties can increase the risk of relapse. In cases of bipolar disorder, to mitigate this risk, antipsychotic treatment may be extended for several months after the resolution of mania and psychosis. For chronic diseases like schizophrenia and delusional disorder, long-term treatment becomes necessary. When adhered to properly, it can significantly reduce relapse rates. However, certain patients may not respond to drug treatment, suggesting a treatment-refractory illness. In these instances, clozapine or electroconvulsive therapy may be employed.

It is important to note that response to antipsychotic treatment in acute schizophrenia may occur within hours to days. Still, maximal drug response may take weeks, especially for negative symptoms. Atypical antipsychotic agents generally exhibit similar or slightly improved efficacy to typical antipsychotics in treating schizophrenia, with some evidence suggesting they offer slight advantages in addressing negative symptoms and cognitive deficits. However, their primary distinction lies in a more favorable neurological side effect profile. Weight gain and metabolic concerns remain significant challenges in long-term treatment. If there is no response after two weeks, clinical reassessment, including medication adherence evaluation, should be undertaken before considering dose adjustment or switching to another agent.

In conclusion, antipsychotic drugs are pivotal in managing severe mental health conditions. Effective use depends on careful selection, proper adherence, and continuous monitoring of patient response. In certain challenging cases, alternative treatments like clozapine (Clozaril) or electroconvulsive therapy (ECT) may be required. Clozapine and olanzapine (Zyprexa), because of their high metabolic risk, are used as a last resort in treatment-refractory cases.

Antipsychotic drugs help treat acute and chronic psychoses, bipolar illness, and behavioral disorders.

The choice of antipsychotic depends on the patient's clinical condition, potential drug interactions, and sensitivity to side effects.

Short-term treatment helps exacerbate symptoms of delirium, dementia, and Parkinson's disease psychosis. It requires low doses of high-potency typical or atypical agents.

The immediate goals of acute antipsychotic treatment encompass reducing agitation, enhancing thought organization, and mitigating social withdrawal.

However, maintaining treatment adherence can be challenging due to adverse drug events, cognitive impairment, substance misuse, and limited insight. Using long-acting injectable or depot antipsychotics can help prevent psychotic relapses in such cases.

Furthermore, in chronic conditions like schizophrenia and delusional disorder, extending antipsychotic treatment beyond the resolution of symptoms significantly reduces relapse rates.

In instances of treatment-refractory illness, where patients do not respond to standard drug treatments, options like clozapine or electroconvulsive therapy may be considered.